Shots: SK Biopharmaceuticals to receive $100M upfront, $430M milestones, and royalties on sales of product. Arvelle to get exclusive rights to develop and commercialize SK’s Cenobamate in EU SK also […]readmore
Shots: Codexis to receive $3M milestone and NHSc to get exclusive WW rights to develop and commercialize Codexis’s CDX-6114 for phenylketonuria (PKU) In 2017, Codexis & NHSc collaborated to develop […]readmore
Shots: Samsung Bioepis to receive upfront and royalties on sales of products from C-Bridge. C-Bridge to build a pharmaceutical firm AffaMed Therapeutics and further collaborate with Samsung for clinical development, […]readmore
Shots: Evotec to receive upfront, milestones and royalties on sales of product from Galapagos. Galapagos to get WW commercialization rights for developed product, will be responsible for future development and […]readmore
Shots: Merck KGaA to receive $4.2B as total deal value, including $341.76M upfront, up to $3.8B milestones including R&D, regulatory and commercialization. GSK to get worldwide co-development and co-commercialization rights […]readmore
Shots: Xencor to receive $120M upfront, $160M milestones for XmAb24306 program and $180M for IL-15 candidate. Genentech to get worldwide commercialization rights for XmAb24306 & IL-15 program, with Xencor has […]readmore
Shots: The update in the development is based on ASPIRO P-I/II study results assessing AT132 in 12 patients aged≤ 5 yrs. following a pre-IND meeting of AT132 with FDA in […]readmore
Shots: The companies collaborated to develop gene-modified NK Cell therapies using CARs (Chimeric antigen receptor) and TCRs (T cell receptors) in the fields of oncology The focus of the agreement […]readmore
Shots: Curium to get exclusive license to develop and commercialize PyL in EU and Progenics to get royalties on the net sales The focus of the agreement is to advance […]readmore
Shots: Shionogi and UBE Industries collaborates for development of anti-RS (respiratory syncytial) virus drugs to treat Respiratory Syncytial Virus (RSV) infection The focus of the agreement is to combine Shionogi’s […]readmore
Copyright © 2020 Digiqole. All Right Reserved.